We are thrilled to announce two new sponsorship programs designed to  support patients with non-small cell lung cancer (NSCLC) and all solid  tumors. These initiatives aim to make advanced diagnostic testing more  accessible and affordable.

1. St James’ Settlement Sponsorship Scheme for NSCLC Patients

St James’ Settlement has launched a sponsorship scheme offering HKD3,000 for a liquid biopsy test to eligible NSCLC patients.

Eligibility Criteria:

• Hong Kong residents with a valid Hong Kong Identity Card
• Patients of hospitals under the Hospital Authority
• Confirmation from a Hospital Authority doctor for the need for lung  cancer liquid biopsy genetic testing (Medical Referral Letter)
• Diagnosed with non-small cell lung cancer
• Negative results for EGFR ex19del, EGFR L858R, EGFR T790M, and ALK gene tests

For more details, please refer to the latest release from St James’ Settlement.

2. HA Patient Support Scheme for All Solid Tumors

We are pleased to offer a HKD2,000 discount on the  Guardant360 CDx (74-gene) blood test for all solid tumors. This offer is  valid until December 24, 2024, as part of our commitment to making  advanced diagnostic testing more affordable.

Special Offer:Eligible patients can benefit from both schemes, receiving up to HKD5,000 in sponsorship.

Terms and Conditions:

• The discount is applicable only to the Guardant360 CDx (74-gene) blood test.
• Offer valid until December 24, 2024.
• Patients must meet the eligibility criteria specified by the respective sponsorship programs.

Stay tuned for more updates and support initiatives aimed at enhancing patient care and access to advanced diagnostics.